Drug Discovery Company Appoints Chief Medical Officer
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowCarmel-based MBX Biosciences has appointed Dr. Mary Jane Geiger to the newly-created position of chief medical officer. The drug discovery company says Geiger has more than 20 years experience in the field and will supervise its global clinical drug development.
“Mary Jane’s range of experience taking treatments through clinical studies to registration makes her an ideal addition to our team,” said Kent Hawryluk, president and chief executive officer of MBX Biosciences. “Her demonstrated creativity in clinical trial design and strong clinical research background complement our organization’s expertise. She will play a leading role in MBX’s transition into a clinical-stage company.”
Geiger formerly served as vice president in drug development services at ICON and was a senior director at Regeneron Pharmaceuticals and as a vice president at Relypsa.
“MBX’s technology offers differentiated solutions to address unmet medical needs in rare endocrine disease,” said Geiger. “I am excited to join MBX’s proven team and help advance the company’s pipeline through clinical development, registration and commercialization.”
